

CIN- L72200TG1997PLC028374

To
Mr. Kautuk Upadhyay
Chief Manager
National Stock Exchange of India Limited
'Exchange Plaza'. C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400 051

Date: 21.02.2019

Dear Sir,

Sub: Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015


Ref: Your query letter vide No.NSE/LIST/FR/12840 dated Feb 18, 2019

With reference to the cited subject and the above referred letter, we would like to inform you that the standalone limited review report was erroneously skipped at the time of submission of quick results. We sincerely regret for the inconvenience caused. We undertake that in future we shall take utmost care while disseminating any information. In case you need any more information / explanation, the undersigned is obliged to furnish.

Standalone limited review report for the quarter ended December, 2018 is enclosed.

Thanking you
Yours truly

For Celestial Biolabs Limited


Amit Kumar Singh
Director
DIN: 01824426



Encl: a/a

CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
Unaudited Financial Results for the Quarter Ended December, 31st 2018

S.No.	Particulars	Rs In Lacs				
		Quarter Ended		Nine Months Ended		Previous Year Ended
		31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Unaudited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)
I	Income from operations					
	a) Revenue from operations	1246.74	1683.51	1717.77	4599.42	2645.72
	b) Other Income	0.00	0.70	0.04	0.70	0.04
	Total Income	1246.74	1684.21	1717.81	4600.12	2645.76
II	Expenditure					
	a) Cost of raw and packing materials consumed	3.84	5.91	1.39	34.24	10.80
	b) Purchase of Traded Products	906.10	1230.77	1232.30	2924.68	1499.42
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	80.27	20.00	191.89	160.25	276.49
	d) Employee Benefits Expense	31.48	69.33	15.60	130.33	37.33
	e) Depreciation and amortization	192.58	188.27	192.58	573.42	577.74
	g) Finance Cost	0.06	27.85	0.25	0.36	0.35
	h) Other Expenses	24.83	82.61	18.46	582.62	39.38
	Total expenses	1239.16	1624.74	1652.47	4405.90	2441.51
III	Profit / (Loss) before exceptional and extra ordinary items (I-II)	7.58	59.47	65.34	194.22	204.25
IV	Exceptional items	0.00	0.00	0.00	0.00	0.00
V	Profit / (Loss) before tax (III - IV)	7.58	59.47	65.34	194.22	204.25
VI	Tax expense	0.00	0.00	0.00	0.00	25.69
VII	Net Profit / (Loss) for the period (V-VI)	7.58	59.47	65.34	194.22	178.56
VIII	Other Comprehensive Income,					
IX	Total Other Comprehensive Income, net of Tax	0.00	0.00	0.00	0.00	0.00
X	Total Comprehensive Income for the period	7.58	59.47	65.34	194.22	178.56
XI	Paid-up Equity Share Capital (Face Value of Rs. 10/- per share)	2258.63	2258.63	2258.63	2258.63	2258.63
	Earning Per Share for the Period					
	Basic	0.03	0.26	0.29	0.86	0.79
	Diluted	0.03	0.26	0.31	0.86	0.79

For CELESTIAL BIOLABS LIMITED

Managing Director

Notes

- 1) The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 14.02.2019
- 2) Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules,2015 as amended from time to time.
- 3) The Company is engaged in the business of "Herbal Products" and therefore, has only one reportable segment in accordance with Ind AS 108 " Operating Segment".
- 4) The Financial results and other financial information for the quarter ended 31st December,2018 has been compiled by the management as per Ind AS, after exercising necessary due diligence , to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any limited review or audit.
- 5) No investor Complaints were received for Quarter Ended 31st December,2018
- 6) The Financial results of the Company for the Quarter Ended 31st December,2018 have been filed with the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and are available in Company's website: www.celestiaibiolabs.com

HYDERABAD
Date: 14.02.2019

FOR CELESTIAL BIOLABS Limited

Managing Director
MANAGING DIRECTOR



B V SWAMI & CO.,

CHARTERED ACCOUNTANTS

Flat No. 101, Sridevi Apartments,
Hindi Nagar Colony, Punjagutta,
Hyderabad - 500 082.

Ph : 040-23350300

E-mail : cachandrasekharv@gmail.com
girishputha@gmail.com

LIMITED REVIEW REPORT

To

The Board of directors of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited standalone financial results of M/s Celestial Biolabs Limited for the period ended 31st December ,2018", being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 05, 2016.

The Preparation of Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, interim financial reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and read with SEBI Circular NO.CIR/CFD/FAC/62/2016 dated July 05, 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these Financial Statements based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial Results , prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 including the manner in which it is to be disclosed or that it contains any material misstatement.

For B V Swami & Co.,
Chartered Accountants
Firm Reg No. 009151S


CA. Chandrasekhar V

Partner
M.No. 223399

Place : Hyderabad
Date: 14.02.2019

